SEEKYO® is a privately owned biotech company focusing on providing cancer patients with improved treatment options that limit adverse effects of standard chemotherapy.

We are developing the next generation of selective drug delivery systems designed to treat solid and hematological cancers.

We are targeting cancer cell and tumor microenvironment specificities.